Skip to content

Diet Intervention and GEnetic STudy (DIGEST-Pilot)

Dietary Intervention Trial to Understand the Mechanism Underlying the 9p21 Variant Interaction With High Fruits and Vegetable Consumption

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01658137
Acronym
DIGEST
Enrollment
84
Registered
2012-08-06
Start date
2012-07-31
Completion date
2016-12-31
Last updated
2016-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood Pressure, Cardiovascular Diseases, Dyslipidemias, Hyperglycemia, Inflammation

Keywords

diet, dietary pattern, gene, gene expression, epigenomics, diet-gene interaction, inflammation, 9p21, fruits, vegetables

Brief summary

Genetic factors contribute to risk factors for cardiovascular disease, such as blood lipids, blood pressure, obesity, diabetes, and may also influence dietary choices, physical activity, and responses to stress. The most robust genetic variant associated with myocardial infarction (MI) is the 9p21 variant, which may raise the risk of MI by up to 40% in those who carry 2 copies of the gene. The investigators recently found that among those who carry the 9p21 variant, the risk of MI may be turned off if individuals eat a diet high in fruits and vegetables. The investigators seek to determine how a prudent or anti-inflammatory diet interacts with the 9p21 risk allele to alter the risk of MI.

Detailed description

Cardiovascular disease (CVD) is the leading cause of death globally. The majority of CVD is explained by conventional risk factors including cigarette smoking, abnormal lipids, high blood pressure, obesity, diabetes, and health behaviours including dietary intake, physical activity, and psychosocial stressors. Genetic factors contribute to the development of these risk factors, and directly to CVD through other novel pathways. Since the advent of high throughput chip-based genotyping, more than 30 genetic variants have been found to be associated with myocardial infarction. The most robust genetic variant which has been consistently associated with myocardial infarction and other forms of arterial disease is the 9p21 variant. This genetic variant located on Chromosome 9 is common in the population, with 50% of people carrying one copy of the risk allele, and an additional 25% of the population carrying two copies of the risk allele. Compared with those with no copies of the risk allele, the risk of myocardial infarction with one copy of the risk allele is 15-20% higher, and the increased risk among carriers of 2 risk alleles is 20-40%. To date the exact mechanism by which the 9p21 variant increases the risk of myocardial infarction is unknown, although some data suggests that other genes and pathways associated with cell proliferation and inflammation are involved. Recently we made the observation that among carriers of the 9p21 variant, the risk of MI may be turned off if individuals consumed a diet high in fruits and vegetables. However the mechanism underlying this interaction is unknown. We seek to discover how a Prudent (i.e. anti-inflammatory) diet interacts with the 9p21 risk allele(s) to alter the risk of myocardial infarction. We postulate that a Prudent diet (i.e. a diet high in fruits, vegetables, whole grains, non-processed foods) in comparison to a Western or inflammatory diet (eg, a typical North American diet high in saturated fats and processed foods) will differentially alter the gene expression (measured by RNA) of the 9p21 locus, change the epigenetic marks in this region, and alter several inflammatory markers suspected to mediate the effect of 9p21 on CVD risk (eg, hs-CRP, IF-alpha21, IFN-γ , interleukin 1-alpha, interleukin 1-beta, and interleukin 6) among people with one or two copies of the risk allele compared to people without the risk allele. The proposed study offers an unique approach to studying dietary relationships with endpoints believed to be influenced by 9p21 gene variants. Rather than testing nutritional supplements, our results will be generalizable to the setting of most dietary counseling practices, which aim to alter dietary patterns, not specific nutrients. This trial will help us to unravel the basis for gene-diet interactions and gain a greater understanding of how inflammation is linked to the development of atherosclerosis, CVD, and possibly some cancers.

Interventions

This intervention lasts 2 weeks (14 days).

OTHERTypical Western Diet

This intervention lasts 2 weeks (14 days).

Sponsors

McMaster University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* 18-80 years old * non-smokers * Body-Mass-Index \<=30 kg/m\^2 * willing and able to cook, prepare, and eat provided study foods

Exclusion criteria

* Aged below 18 years or above 80 years * current tobacco smoking * Body mass index above 30 kg/m2 * Unwillingness or inability to cook, prepare and eat provided study foods (e.g. for medical, philosophical, or religious reasons) * Excessive use of alcohol (\>14 drinks/week in men; \>7 drinks/week in women) * Significant morbidity that would interfere with participation or assessment, including : * Cancer * HIV * chronic renal disease * renal failure * Hepatitis/Jaundice * Liver Disease * Chronic Obstructive Pulmonary Disease * Inflammatory bowel disease (Crohn's / Colitis) * High blood or urine sugar/diabetes * High blood cholesterol or triglycerides * Angina/Heart attack/Coronary artery disease * Heart failure * Other heart disease * Angioplasty (balloon opening of an artery) or coronary bypass surgery * Medications or nutritional supplements (including multivitamins) that could affect outcome measurements. Excluded medications would include: * Lipid/cholesterol lowering pills * Insulin/oral hypoglycemic agents * Medication for stroke * Antibiotics * oral contraceptives * hormone replacement therapy * non-steroidal anti-inflammatory drugs * corticosteroids * unwillingness to stop nutritional supplements 1 week prior to and for duration of intervention * anticipated difficulties maintaining body weight (e.g. athletic training)

Design outcomes

Primary

MeasureTime frame
gene expression measuring ANRIL productionbaseline and 2 weeks
epigenetic marksbaseline and 2 weeks

Secondary

MeasureTime frameDescription
high-sensitivity C-reactive proteinbaseline and 2 weeksBiomarker of inflammation
interferon-alpha-21baseline and 2 weeksBiomarker of inflammation
interferon-gammabaseline and 2 weeksBiomarker of inflammation
interleukin-1-alphabaseline and 2 weeksBiomarker of inflammation
total cholesterolbaseline and 2 weekslipid risk factor for cardiovascular disease
low-density lipoprotein-cholesterolbaseline and 2 weekslipid risk factor for cardiovascular disease
high-density lipoprotein-cholesterolbaseline and 2 weekslipid risk factor for cardiovascular disease
apolipoprotein-Bbaseline and 2 weekslipid risk factor for cardiovascular disease
fasting glucosebaseline and 2 weeksindicator of insulin resistance
systolic blood pressurebaseline and 2 weeksmmHg
diastolic blood pressurebaseline and 2 weeksmmHg
interleukin-6baseline and 2 weeksBiomarker of inflammation

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 1, 2026